Predicting drug–drug interactions in breast cancer patients treated with CDK4/6 inhibitors and forward planning Review
| Authors: | Kulkarni, A.; Singh, J. |
| Review Title: | Predicting drug–drug interactions in breast cancer patients treated with CDK4/6 inhibitors and forward planning |
| Abstract: | Introduction: Cyclin-dependent kinase (CDK) 4/6 inhibitors are cornerstones in the treatment of Hormone Receptor (HR) positive and Human Epidermal Growth factor (HER2) negative metastatic breast cancer. Given their widespread use in the metastatic setting and emerging use in the adjuvant setting, studying drug–drug interactions (DDI) of these medications is of utmost importance. Areas covered: This review provides key background information on the CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib. We discuss drug–drug interactions including those with proton pump inhibitors as well as CYP3A substrates, inhibitors, and inducers. We describe the effect of these drugs on membrane transporters and their substrates as well as those drugs that increase risk of CDK4/6 toxicities. Finally, we explore future directions for strategies to minimize drug–drug interactions. Expert opinion: It is crucial to be mindful of medications that may interfere with drug absorption, such as proton pump inhibitors, as well as those that interfere with drug metabolism, such as CYP3A4 inhibitors and inducers. Additionally, special consideration should be given to populations at higher risk for polypharmacy, such as older patients with greater comorbidities. These interactions and patient characteristics should be considered when developing individual treatment plans with CDK4/6 inhibitors. © 2024 Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | review; drug potentiation; treatment planning; antineoplastic agents; pyridines; antineoplastic agent; liver toxicity; breast cancer; breast; protein kinase inhibitor; midazolam; qt prolongation; breast neoplasms; oncology; protein kinase inhibitors; body mass; proton pump inhibitor; gene interaction; breast tumor; drug monitoring; drug metabolism; drug absorption; simvastatin; dose calculation; drug interactions; benzimidazole derivative; benzimidazoles; multidrug resistance; cyclin dependent kinase 4; pharmacokinetics; pyridine derivative; cyclin-dependent kinase 4; drug interaction; cyclin dependent kinase 6; cyclin-dependent kinase 6; cytochrome p450 3a4; synergistic effect; cdk4 protein, human; humans; human; female; palbociclib; abemaciclib; aminopyridines; ribociclib; aminopyridine derivative; proton pump inhibitors; cdk4/6 inhibitors; abc transporter subfamily b; qtc interval; cytochrome p450 3a inducer; cytochrome p450 3a inhibitor; drug–drug interactions; cdk6 protein, human |
| Journal Title: | Expert Opinion on Drug Metabolism and Toxicology |
| Volume: | 20 |
| Issue: | 4 |
| ISSN: | 1742-5255 |
| Publisher: | Informa Healthcare |
| Date Published: | 2024-01-01 |
| Start Page: | 225 |
| End Page: | 233 |
| Language: | English |
| DOI: | 10.1080/17425255.2024.2341810 |
| PUBMED: | 38600865 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
